GSK: primary endpoint reached in ovarian cancer
(CercleFinance.com) - GSK announced on Friday that a Phase III trial combining two of its drugs met its primary endpoint in the first-line treatment of advanced ovarian cancer.
The combination of the antibody Zejula and the anticancer drug Jemperli demonstrated a 'statistically significant' difference in progression-free survival.
The British laboratory, which focuses on gynecological cancers, says that the secondary endpoint was not met, but that it is currently conducting further analysis before sharing the data with regulatory authorities and at scientific congresses.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The combination of the antibody Zejula and the anticancer drug Jemperli demonstrated a 'statistically significant' difference in progression-free survival.
The British laboratory, which focuses on gynecological cancers, says that the secondary endpoint was not met, but that it is currently conducting further analysis before sharing the data with regulatory authorities and at scientific congresses.
Copyright (c) 2024 CercleFinance.com. All rights reserved.